Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
The University of Texas MD Anderson Cancer Center · University Hospital Cologne · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
413
total citations
- FWCI
- 56.51
- Percentile
- 100%
- References
- 39
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- Medicine
- Response Evaluation Criteria in Solid Tumors
- Population
- Internal medicine
- Oncology
- Clinical endpoint
- Adverse effect
- Interim analysis
No related works found for this paper.
Funding
- ELEli Lilly and Company
- CPCancer Prevention and Research Institute of TexasAward: RP1100584
- NINational Institutes of HealthAwards: R01CA242845, R01CA273168
- UOUniversity of Texas MD Anderson Cancer CenterAwards: RO1 CA259177, P30 CA008748, RO1 CA251591, RO1 CA226864, P30 CA016672
- CFCenter for Clinical and Translational Sciences, University of Texas Health Science Center at HoustonAward: UL1 TR000371
- SKSheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer TherapyAward: 1U01 CA180964